|
|
|
Construction and humoral immune response of Epstein-Barr
virus latent membrane protein 2 DNA vaccine in mice |
| Jianqing PAN PhD1,Qin ZHANG MD2,Daowen WANG MD, PhD2, |
| 1.Department of Internal
Medicine, Tongji Hospital, Tongji Medical college, Huazhong University
of Science and Technology, Wuhan 430030, China；Research Center for
Neural Engineering, Shenzhen Institute of Advanced Technology, Chinese
Academy of Science, Shenzhen 518055, China; 2.Department of Internal
Medicine, Tongji Hospital, Tongji Medical college, Huazhong University
of Science and Technology, Wuhan 430030, China; |
|
|
|
|
Abstract We constructed a eukaryotic expression plasmid encoding Epstein-Barr virus latent membrane protein 2 (EBV, LMP2) and evaluated its effects on humoral immunity. First, the encoding sequence of the EBV LMP2 was amplified from B95−8 cell RNA by reverse transcription polymerase chain reaction (RT-PCR) and then was directionally cloned into eukaryotic expression vector pcDNA3.1. It was employed to evaluate immune response of the mice inoculated doubly with the DNA vaccine. The serum antibody against LMP2 was detected with enzyme-linked immunosorbent assay (ELISA). The recombinant plasmid pcDNA3.1-LMP2 was confirmed by the restrictive endonuclease analysis and sequence analysis. The serum titer of IgG antibody against LMP2 epitope in the mice immunized with the DNA vaccine encoding LMP2 was up to 1∶4000. In conclusion, the EBV LMP2 DNA vaccine can induce a strong humoral immune response in mice.
|
| Keywords
Epstein-Barr virus
latent membrane protein 2
nasopharyngeal carcinoma
humoral immunity
|
|
Issue Date: 05 December 2009
|
|
|
Dolan A, Addison C, Gatherer D, Davison A J, McGeoch D J. The genome of Epstein-Barrvirus type 2 strain AG876. Virology, 2006, 350(1): 164–170
doi: 10.1016/j.virol.2006.01.015
|
|
Mourad W, Alsohaibani M O, Saddik M, Bazerbashi S. Epstein-Barrvirus expression in Hodgkin’s disease: Correlation with histologicsubtypes and T and B lymphocyte distribution. Ann Saudi Med, 1998, 18(4): 296–300
|
|
Yilmaz A, Hazar V, Akcam M, Inanc-Gurer E, Ceken K, Artan R. Burkitt’s lymphoma following a pediatric livertransplantation: predictive negative value of serologic response toEpstein-Barr virus. Turk J Pediatr, 2007, 49(4): 434–436
|
|
Jung I M, Chung J K, Kim Y A, Kim J E, Heo S C, Ahn Y J, Hwang K T, Kim B G, Lee K L, Kim C W, Kim W H, Chang M S. Epstein-Barr virus, beta-catenin,and E-cadherin in gastric carcinomas. JKorean Med Sci, 2007, 22(5): 855–861
doi: 10.3346/jkms.2007.22.5.855
|
|
Villa M L, Bombardieri E. LYDMA-antigens and immunityagainst EBV-infected cells Epstein-Barr virus as a model for the studyof host-infection interaction. Int J BiolMarkers, 1987, 2(2): 125–132
|
|
Ten Napel C H, The T H, Van Egten-Bijker J, de Gast G C, Halie M R, Langenhuysen M M. Discordance of Epstein-Barr Virus (EBV)specific humoral and cellular immunity in patients with malignantlymphomas: elevated antibody titres and lowered in vitro lymphocyte reactivity. Clin Exp Immunol, 1978, 34(3): 338–346
|
|
Feltkamp M C, Smits H L, Vierboom M P, Minnaar R P, de Jongh B M, Drijfhout J W, ter Schegget J, Melief C J, Kast W M. Vaccination with cytotoxic T lymphocyte epitope-containingpeptide protects against a tumor induced by human papillomavirus type16-transformed cells. Eur J Immunol, 1993, 23(9): 2242–2249
doi: 10.1002/eji.1830230929
|
|
Cheung A K, Lung H L, Hung S C, Law E W, Cheng Y, Yau W L, Bangarusamy D K, Miller L D, Liu E T, Shao J Y, Kou C W, Chua D, Zabarovsky E R, Tsao S W, Stanbridge E J, Lung M L. Functional analysis of a cell cycle-associated, tumor-suppressivegene, protein tyrosine phosphatase receptor type G, in nasopharyngealcarcinoma. Cancer Res, 2008, 68(19): 8137–8145
doi: 10.1158/0008-5472.CAN-08-0904
|
|
Armstrong R W, Imrey P B, Lye M S, Armstrong M J, Yu M C, Sani S. Nasopharyngeal carcinoma in Malaysian Chinese: saltedfish and other dietary exposures. Int JCancer, 1998, 77(2): 228–235
doi: 10.1002/(SICI)1097-0215(19980717)77:2<228::AID-IJC11>3.0.CO;2-7
|
|
Sanguineti G, Bossi P, Pou A, Licitra L. Timingof chemoradiotherapy and patient selection for locally advanced nasopharyngealcarcinoma. Clin Oncol (R Coll Radiol), 2003, 15(8): 451–460
doi: 10.1016/S0936-6555(03)00201-2
|
|
Cheng S H, Yen K L, Jian J J, Tsai S Y, Chu N M, Leu S Y, Chan K Y, Tan T D, Cheng J C, Hsieh C Y, Huang A T. Examining prognostic factors and patterns of failure in nasopharyngealcarcinoma following concomitant radiotherapy and chemotherapy: impacton future clinical trials. Int J RadiatOncol Biol Phys, 2001, 50(3): 717–726
doi: 10.1016/S0360-3016(01)01509-7
|
|
Nguyen-Van D, Ernberg I, Phan-Thi Phi P, Tran-Thi C, Hu L. Epstein-Barr virus geneticvariation in Vietnamese patients with nasopharyngeal carcinoma: full-lengthanalysis of LMP1. Virus Genes, 2008, 37(2): 273–281
doi: 10.1007/s11262-008-0262-9
|
|
Duraiswamy J, Sherritt M, Thomson S, Tellam J, Cooper L, Connolly G, Bharadwaj M, Khanna R. Therapeutic LMP1 polyepitopevaccine for EBV-associated Hodgkin disease and nasopharyngeal carcinoma. Blood, 2003, 101(8): 3150–3156
doi: 10.1182/blood-2002-10-3092
|
|
Duraiswamy J, Bharadwaj M, Tellam J, Connolly G, Cooper L, Moss D, Thomson S, Yotnda P, Khanna R. Induction of therapeutic T-cell responses to subdominanttumor-associated viral oncogene after immunization with replication-incompetentpolyepitope adenovirus vaccine. CancerRes, 2004, 64(4): 1483–1489
doi: 10.1158/0008-5472.CAN-03-2196
|
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
| |
Shared |
|
|
|
|
| |
Discussed |
|
|
|
|
